Santa Maria ag forum focuses on challenges
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen donations to CSUCI developing STEM ecosystem
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen buys $66 million stake in genetics device company
Thousand Oaks biotech giant Amgen broadened its reach into genetics research Oct. 18 with a $66 million investment in handheld DNA sequencing company Oxford Nanopore Technologies. Genetics has been a research focus for Amgen since its 2012 acquisition of deCODE, particularly in the area of Alzheimer’s therapies. The news follows closely the release by Oxford Read More →
Read More →Amgen studying genes to target pain conditions
For the next year, Amgen and Boston Children’s Hospital will use genetic analysis to study pain sensitivity. The biotech giant based in Thousand Oaks will work with patients who have abnormal pain conditions, and the hospital will validate genetic markers as potential targets for new therapies, the two announced in a press release on Oct. 16. “Traditional Read More →
Read More →Amgen buys DeCode Genetics for $415M
Biotech giant Amgen is buying Icelandic genetics research firm DeCode Genetics for $415 million, the Thousand Oaks company said Dec. 10. The all-cash deal is expected to close before the end of the year and will give Amgen, the largest biotechnology firm in the world, opportunities to develop new medicines that target defective DNA. “DeCode Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
